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Abstract
Background: The human genome contains a large amount of cis-regulatory DNA elements responsible for
directing both spatial and temporal gene-expression patterns. Previous studies have shown that based on their
mRNA expression breast tumors could be divided into five subgroups (Luminal A, Luminal B, Basal, ErbB2+ and
Normal-like), each with a distinct molecular portrait. Whole genome gene expression analysis of independent sets of
breast tumors reveals repeatedly the robustness of this classification. Furthermore, breast tumors carrying a TP53
mutation show a distinct gene expression profile, which is in strong association to the distinct molecular portraits.
The mRNA expression of 552 genes, which varied considerably among the different tumors, but little between two
samples of the same tumor, has been shown to be sufficient to separate these tumor subgroups.
Results: We analyzed in silico the transcriptional regulation of genes defining the subgroups at 3 different levels: 1.
We studied the pathways in which the genes distinguishing the subgroups of breast cancer may be jointly involved
including upstream regulators (1st and 2nd level of regulation) as well as downstream targets of these genes. 2.
Then we analyzed the promoter areas of these genes (−500 bp tp +100 bp relative to the transcription start site) for
canonical transcription binding sites using Genomatix. 3. We looked for the actual expression levels of the identified
TF and how they correlate with the overrepresentation of their TF binding sites in the separate groups. We report
that promoter composition of the genes that most strongly predict the patient subgroups is distinct. The class-
predictive genes showed a clearly different degree of overrepresentation of transcription factor families in their
promoter sequences.
Conclusion: The study suggests that transcription factors responsible for the observed expression pattern in breast
cancers may lead us to important biological pathways.
Background
Previous studies have shown that breast tumors can be
divided into five subgroups (Luminal A, Luminal B, Nor-
mal-like, ErbB2 over-expressing, and Basal-like) based on
their mRNA expression patterns [1]. These patterns have
been validated in independent datasets representing dif-
ferent laboratories, platforms and different patient
cohorts [2]. Survival analyses on a sub-cohort of patients
with locally advanced breast cancer showed a significant
difference in outcome of the patients in the various ex-
pression subgroups, with poor prognosis for the ErbB2+
and basal-like subtypes [2]. The expression of 552 genes,
the intrinsic gene list, has been suggested to be sufficient
to separate breast carcinomas into the five distinct
subgroups. What mechanisms of common regulation
make these genes cluster together? We have previ-
ously shown that we can separate the patient clusters
based only on the promoter composition of single
binding sites in the promoters of the genes from the
intrinsic gene list [3]. However, regulation of gene ex-
pression in eukaryotes is highly complex and depends
on sets of TFs rather than individual TFs [4] and
in this study we attempt to characterize the overrepre-
sentation of entire TF families. The promoter
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composition of the genes is one of the major determi-
nants of gene regulation including multiple transcrip-
tion binding sites that interact with a specific
combination of transcription factors (TF). Eukaryotes
achieve this diversity by combining a small number of
transcription factors whose activities are modulated by
diverse sets of conditions [5]. Different functionalities
can be conferred on one TF by its association with dif-
ferent co-factors. These factors may act as global TFs
that assist their gene-specific partners in their function,
and may thus activate or repress transcription depend-
ing on the partner motif and the condition [5]. Analyz-
ing transcription network dynamics in yeast, Luscombe
et al. showed that, in response to diverse stimuli, tran-
scription factors may alter their interaction patterns to
varying degree, thereby rewiring the network [6]. While
few transcription factors serve as permanent hubs, most
of them act transiently during certain conditions. Ex-
ogenous processes like environmental responses facili-
tated fast signal transductions to multiple genes with
short regulatory cascades, whereas endogenous pro-
cesses needed to progress through multiple stages with
a complex combination of TFs to fewer target genes [6].
The same TFs may act both in endogenous and exogen-
ous processes. Regulatory hubs targeting disproportion-
ately large numbers of genes and thereby representing
the most influential components of a network- have
been described. Both Pilpel [5] and Luscombe [6] con-
cluded that precise regulation of a condition cannot
arise from the specificity of individual TFs, therefore
combinatorial TF usage seems to be the key. The NF-κB
family of TFs is an example of transcription regulators
that are activated by both intra- and extra-cellular stim-
uli such as cytokines, oxidant-free radicals, ultraviolet ir-
radiation, and bacterial or viral products [7]. Aberrant
NF-κB activity has been implicated in carcinogenesis
and in the control of cellular response to anti-cancer
agents. Activated NF-κB was detected predominantly in
ER-negative breast tumors, and mostly in the ErbB2-
over-expressing tumor subgroup [8].
Methods
The in silico analysis of the transcriptional regulation
of genes defining the subgroups was performed at
three different levels: (1) Study of the pathways in
which the genes distinguishing the subgroups of
breast cancer may be jointly involved including up-
stream regulators (1st and 2nd level of regulation) as
well as downstream targets of these genes. (2) Then
we analyzed the promoter areas of these genes (−500
bp tp +100 bp relative to the transcription start site)
for canonical transcription binding sites using Geno-
matix. (3) We looked for the actual expression levels
of the identified TF and how they correlate with the
overrepresentation of their TF binding sites in the
separate groups.
Selection of genes
The expression of 552 genes, the intrinsic gene list,
which has been suggested to be sufficient to separate
breast carcinomas into the five distinct subgroups
defined in [1] and [2,9] was used for the pathway analysis
in this study (referred to as full list). A subset consisting
of 197 genes [10] that best represented the classification
scheme in breast cancer (referred as top list) were
selected from the intrinsic list, and used in the promoter
analysis part (Additional file 1: Table S1).
Pathway analysis
Pathway analysis was performed using Pathway Studio
[11] from Ariadne Genetics. Two network prediction
algorithms were used that allow to discover the patterns
of gene expression inherent in the experimental data:
Pearson Correlation and Auto Net Finder network pre-
diction algorithm. Pathway Studio’s text mining tools
were applied to extract biological associations by mining
PubMed to build pathways from extracted facts using
data from recent publications and public and commer-
cial databases such as KEGG, BIND, GO, and the
PathArt database of curated signaling and disease path-
ways. The algorithm for building Correlation Network in
Pathway Studio is based on Pearson Correlation. Genes
with similar expression profiles are connected with edges
indicating the significance of the correlation. The group
of tightly correlated genes form cluster in the correlation
network. The algorithm can be used for clustering genes
according to their expression profiles across multiple
samples. The tool calculates correlation coefficients be-
tween all pairs of gene expression profiles measured in
the experiment and outputs clusters of highly correlated
genes. Identified gene clusters can be further validated
and analyzed using relations from the database that have
been extracted from the literature by Ariadne Genetics.
Auto Net Finder is a network estimation system that
combines hierarchical clustering and Graphical Gaussian
Modeling and is used for distinguishing direct and indir-
ect relationship among variables. Bibliosphere pathways
(release 7.1) [12] (http://www.genomatix.de, Genomatix
Software GmbH) was used for extracting the associations
between gene, transcription factor and proteins corre-
sponding with the genesets defining each molecular sub-
type of breast cancer. Genomatix Bibliosphere is a
knowledge database consisting of manually curated co-
cited genes in PubMed, which additionally provides in-
formation about the presence of TFBS in their promo-
ters, using in silico tool- MatInspector, interactions and
associated pathways from Molecular Interactions data-
base-NetPro and BioCyc, respectively.
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Analysis of overrepresentation of TFBS families in the
promoter sequences
We extracted the putative regulatory promoter regions
from 500 bp upstream to 100 bp downstream of RefSeq
promoters of the subtype-associated genes. Further ana-
lysis was based on the hypothesis that overrepresentation
of potential transcription factor binding site (TFBS)
motifs in a set of co-expressed gene promoters may indi-
cate regulatory relationship. In order to emphasize the
functional representation of TFBS motifs overrepre-
sented in a set of promoters, we used the TFBS matrix
family concept. TFBS matrix families are defined as
groups of TFBS weight matrices corresponding to the
same or functionally similar transcription factors. For
any given TF, there could be multiple matrices described
by different independent sources, leading to multiple
matches for similar position or shifting of matches by a
few base pairs. By using the functional domain clustering
based on di/tri/tetra-nucleotide occurrence and addition-
ally function-based subgrouping, TFBS matrices can be
grouped according to their functional similarity, known
as TFBS families [13]. Thus members sharing same TFBS
family are expected to have functional similarity in
addition to binding domain similarity. For estimation of
over-representation of each TFBS family, first occur-
rences of its corresponding TFBS motifs within a set
of subtype-specific promoter sequences was obtained.
Then relative occurrence of each TFBS family was esti-
mated by comparing this observed occurrence to the
rate of occurrence of the same TFBS matrix family in
an equal base-pair long reference background sequences
from human promoter. Overrepresentations of a motif
is measured by two different methods:
1. In terms of fold factor of overrepresentation
compared to the background
Fold factor of TFBS overrepresentation was
calculated by a formula as mentioned below:
r Xð Þ ¼ nobs Xð Þ
nexp Xð Þ
Where, r(X) = fold factor of overrepresentation of a
TFBS family, X
nobs (X) = observed number of hits of X in a given set
of promoter sequences
nexp (X) = expected number of hits of X in an equally
sized sample from genomic promoter background
sequences
2. As z-scores that provide a measure of the distance of
sample from the reference population mean. Here
sample refers to the number of observed hits of any
particular TFBS in a given input set of sequences
and reference refers to the number of hits of the
same TFBS in equally sized human genomic
promoter sequence population.
z Xð Þ ¼ nobs Xð Þ  nexp Xð Þ  0:5
S Xð Þ
z(X) is a z-score of overrepresentation of a transcrip-
tion factor binding site family (X);
nobs (X) is a number of observed hits of X in an input
promoter sequences;
nexp (X) is expected number of hits of X in an equally
sized sample sequences in human genomic promoter
background;
S(X) is a population standard deviation of number of
hits of X
We used Genomatix RegionMiner tool (Genomatix
Software GmbH, http://www.genomatix.de) in order
to evaluate the degree of TFBS family overrepresen-
tation. The histogram of z-scores of each TFBS motif
families in each subtype-specific promoter sequences
is shown in the Additional file 2: Figure S1. Histo-
grams like this indicate that choosing the cut-off
level of 2.0 allows identifying TFBS families that are
overrepresented. However, z-score cut-off level of 2.0
does not provide a precise measure of significance,
because of the disparity of sample size between sam-
ple and reference. Due to the copyright and technical
limitations in accessing the Transfac database, further
statistical testing of over-representation could not be
performed within that tool.
Under-representations or absence of TFBS family
motifs in sub-type specific genes may occur due to a
fewer number of subtype-representative genes and
subsequently a smaller number of promoter
sequences used for any particular subtype. This can
be a source of false positivity. Therefore we have not
taken into account the under-representations of
TFBS family motifs in this analysis.
Principal component analysis to identify TFBS with
maximum variance between subtypes
Principal component analysis (PCA) [14] was per-
formed for ranking the TFBS families with respect to
the variance of fold-factor overrepresentation con-
tributed by them between five subtypes. We prepared
a matrix of TFBS fold-factors for subtypes, with sub-
types as columns and TFBS families as rows. We
performed PCA on this matrix using the princomp
function of Matlab. Subtracting each data point from
the column mean represents a center of this matrix.
Hotelling’sT2 statistic was used as a measure of
multivariate distance of each TFBS family from the
center of the TFBS fold-factor matrix as described in
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[http://www.mathworks.com/help/toolbox/stats/prin-
comp.html].
Gene expression data
We used a subset of the samples (n= 114) from previ-
ously published [15] mRNA expression data [GEO data-
set #GSE19783]. Subtypes were predicted by using the
PAM50 [16].
mRNA expression of the studied TF
Transcription factor families with overrepresentation z-
score >2.0 were mapped to their corresponding probes
in the mRNA expressions dataset. By applying multiclass
SAM, we extracted 120 TF genes with significantly dif-
ferent (at the FDR <0.1) expression between the five
subtypes. Pearson’s correlation between the subtype-spe-
cific geometric mean expression of this subset of tran-
scription factor genes and fold overrepresentation was
computed. The justification of using geometric mean in-
stead of arithmetic mean is that typically mRNA expres-
sion values are log-normally distributed.
Results and discussion
Pathway analysis of the genes that define the five breast
cancer subgroups
Using Pathway Studio from Ariadne Genetics, we studied
the direct interactions between the genes with distin-
guished gene expression pattern in the breast cancer
subgroups as described in Materials and Methods, selec-
tion of genes. Most profound direct interactions were
observed for the genes defining the luminal A group
with protein-protein interactions between XBP1 and
ESR1 and CCND1 (Additional file 3: Figure S2). Trefoil
(TFF3) has been functionally coupled to CCND1 through
angiotensin receptor 1 (AGTR1). Angiotensin II is con-
verted from its precursor by angiotensin I-converting en-
zyme (ACE) and has been shown to mediate growth in
breast cancer cell lines via ligand-induced activity
through the angiotensin II type 1 receptor (AGTR1). We
also searched for upstream regulators as well as down-
stream targets of these genes. Downstream targets could
be observed centered at the ESR1, MYC, NFKB1,
GATA3, CCND1, TP53 and MSX2/FOXC1 (Additional
file 4: Figure S3).
A somewhat less organized pathway structure is
observed in the luminal B subclass. The ESR1 node was
not observable and the TP53 network was more sparse
with fewer partner genes. Novel nodes were centered at
NRG1, GSTP1 and CUL1 (Additional file 5: Figure S4),
CUL1 has homology to yeast Cdc53, which is part of a
complex known as SCF that mediates the ubiquitin-
dependent degradation of G1 cycles and cyclin-
dependent kinase inhibitors, while NRG1 contains a do-
main related to the epidermal growth factor family of
ligands and can act as receptor agonists. The direct
interactions between genes highly expressed in Luminal
B subtype were observed between GSTP1 and CDK2AP1,
S100A10 and S100A11 and PPP1R13B and TP53BP2.
The latter protein interacts with TP53 to specifically en-
hance p53-induced apoptosis but not cell cycle arrest.
Four distinct regulatory nodes were observed in the
ERBB2 group: around the ERBB2 itself, TP53, NFKB1
and CTNNB1 (cadherin-associated protein, beta 1)
(Additional file 6: Figure S5). NFkB-p65 was shown to
repress β-catenin-activated transcription of cyclin D1
[17]. Moreover, a direct interaction is established be-
tween ERBB2 and GRB7 (Additional file 3: Figure S2).
The solution structure of the Grb7-SH2/erbB2 peptide
complex was described and suggested to be involved in
cell signaling pathways that promote the formation of
metastases and inflammatory responses. PPARBP, which
is co-amplified with ERBB2, has in early studies been
suggested to play a role in mammary epithelial differenti-
ation and in breast carcinogenesis by its ability to func-
tion as ESR1 coactivator. It was shown to contain a
typical CCAT box and multiple cis-elements such as C/
EBPbeta, YY1, c-ETS-1, AP1, AP2, and NFkappaB bind-
ing sites. The 4 different regulatory nodes are connected
by FLOT2, the human epidermal surface antigen
involved in epidermal cell adhesion. NFKB1 was present
in the network for the Basal group, where also the FOX
family, a whole family of cyclins and CDK2, and CDK6
and isoforms of protein kinase (RPS6K) were present
(Additional file 7: Figure S6). Interestingly, a large num-
ber of connections lead to GJA1 (Cap junction protein,
alpha, also known as connexin 43). Other distinct nodes
around TP53 are those connecting to KRT5, MAPK sig-
nalling, E2F1 and NCL. NCL, Nucleolin, one of the most
abundant nucleolar proteins, has been recently shown to
be involved in the reprogramming of somatic cells for
derivation of either embryonic stem (ES) cells, by som-
atic cell nuclear transfer (SCNT), or ES-like cells, by
induced pluripotent stem (iPS) cell procedure. Nucleolar
proteins are proposed to be the markers of activation of
embryonic genes [18] and provide mechanism for nucle-
olar control of progression of cell cycle in stem cells and
cancer cells [19]. TP53 was a central node in the regula-
tory network of the normal-like subgroup, surrounded
by JUN, ACSS2, ACSL1, KRT13, PIK3R1 and other
nodes some representing glycolysis, energy metabolism,
pyruvate metabolism and metabolism of carbohydrate
(Additional file 8: Figure S7).
Noteworthy, a TP53 network node was observed in
each of the studied expression subclasses shown here
(Additional file 4: Figure S3, Additional file 8: Figures
S7). It is of interest to note that in every case TP53 was a
hub in a somewhat different neighborhood. While in the
basal subtype TP53 was connected to CDK6, a cyclin-
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dependent protein kinase (CDKs) that regulate major cell
cycle transitions and CDH3, cadherin 3, as well as FZD7
and KRT5, in the luminal A tumors one could observe
detoxifying enzymes such as NAT1, CYP2A6 as well as
the retinoic acid receptor RARRES3 in the TP53 hub
(Figure 1).
Over-representation of specific transcription factor
binding sites in the promoter of the genes that
distinguish the subtypes
The correlation matrix of TFBS fold-overrepresentation
vectors for the five subtypes shows positive correlation
in terms of potential TFBS family overrepresentation be-
tween 1. ERBB2+ and basal subtypes (0.27); 2. Luminal B
and ERBB2+ (0.16); 3. Luminal A and luminal B (0.11).
In order to visualize the differential TFBS overrepresen-
tation, we performed the principal component analysis
(PCA). PCA plot (Figure 2) displays the significant differ-
ences between the subtypes in terms of fold-factor of
motif frequencies observed in promoter sequences of
subtype-associated gene promoters compared to their
corresponding normal frequencies in genomic promoter
sequences. Distances between points representing the
TFBS matrix families are the multivariate distances of
fold-factor overrepresentation of each TFBS family in
each of the subtype. This indicates that the shorter the
distance, the greater similarity in fold-overrepresentation
of that particular TFBS family in given subtypes. More
than 60% and 76% of cumulative variance is captured by
first two components and first three principal compo-
nents, respectively. The top ten ranking TFBS families in
distance from center and some of the functionally signifi-
cant TFBS families are specifically labeled in the PCA
plot. Biplots of first and second principal components
show differentially overrepresentated TFBS families be-
tween the normal-like and rest of the subtypes. Biplot of
second and third principal components shows TFBS fam-
ily overrepresentations in luminal B. Differential TFBS
family representations between ERBB2+ and basal groups
cannot be seen in biplots of first three principal compo-
nents, but can be visualized in a biplot of first and fourth
principal components. In the first principal component,
V$BTBF, V$PAX1, V$PAX4 and V$TCFF are the major
contributors of variance, where as V$PAX4, V$GUCE,
ASF1A
MUC1
SDHA
BECN1
TMSB10
SERPINH1
REEP5
CREB1
TP53
FLT1
CYP2A6
CTNNB1
EBNA1BP2
VCL
AKR1C1
PLAT
CDH3
NAT1
AQP3
HSF1
CDK6
KRT13
PAX8
BTG3
TP63
FZD7
LRBA
CEBPB
SNED1
SHC2
KRT5
RARRES3
Figure 1 Predicted functional relationship of TP53 in different molecular subtypes of breast cancer. Figure shows predicted interactions of
genes or proteins with TP53. Source: Bibliosphere pathway database. (green edges: TF motif match found in target promoter of target genes; genes
associated with basal subtype are shown as red nodes, ones with luminal A in blue, luminal B in cyan and normal-like as green nodes.)
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V$ARID are the major contributors of variance in the sec-
ond principal component.
Several of the gene clusters shared cis-elements that
were present in more than 90% of the promoters. For
the top six genes that classify the ErbB2+ over-expres-
sing cluster, four TFBSs were found to be present in
100% of the promoters. These were NOLF (Neuron-spe-
cific-olfactory), ETSF (E26 Transformation-Specific fac-
tor 1), STAT (the Signal Transducers and Activator of
Transcription protein) and NF-κB (Nuclear Factor κappa
Beta) (Additional file 9: Table S2). NF-κB is the family of
nuclear factor kappa beta of transcription factors. NF-κB
has been shown to promote cell proliferation, to sup-
press apoptosis, to promote cell migration, and suppress
differentiation [7]. NF-κB binding sites were found
significantly over-represented in the promoters that best
classify the ErbB2+ subgroup compared to the other 4
subgroups (Additional file 9: Table S2; Figure 3B) and
78% of the 27 genes expressed in the basal-like subgroup
had also NF-κB binding site in the promoter. This was in
marked contrast compared to the promoter composition
of the normal-like and luminal subgroups (Figure 3B).
The presence of NF-κB binding sites in the genes from
the ERBB2 and basal groups is in concordance with the
pathway analysis performed on the downstream genes
(see above). The cis-elements PAX1, PAX9 (The paired
box gene 5), MAZF (myc-associated zinc finger) and
EGRF (epidermal growth factor receptor) were overre-
presented in the genes that are over-expressed in the Lu-
minal B subgroup (Additional file 9: Table S2). While the
-0.5
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V$RBIT
V$ZF35
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V$MAZF
V$ARID
V$BTBF
V$GCNR
V$GABF
V$NFKB
O$PTBP
ERBB2
Figure 2 PCA plot of overrepresentated TFBS matrix families. PCA plot shown in terms of fold factor of overrepresentation in each subtype
compared to the reference genomic promoters background. Blue lines represent the Eigen vectors, the direction and length of which indicates
how each subtype variable contributes to the principal components in the plot. TFBS matrix families with maximum distance from the centroid
are labeled on the plot.
Figure 3 Subtypes with relevance to NF-κB binding sites and TP53 mutations. A. The five subtypes shown by hierarchical clustering using
the “intrinsic” gene set. Dendrogram shows the clustering of the tumors into five subgroups. Branches are color-coded. B. Frequency of NF-κB
binding sites in the 5 subgroups; and C. Frequency of TP53 mutations.
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PAX superfamily is involved in a multitude of develop-
mental processes and is required for initiating B cell
lineage and maintaining neural development and sperm-
atogenesis, the MAZF is a common transcription factor
and might play a more general role. The major distinc-
tion between the luminal A and B, both consisting of ER
positive tumors, is the presence of a strong proliferations
cluster in the luminal B subtype. Noteworthy, binding
sites for growth factors and their receptors like EGRF are
over-represented in the promoters of the genes that de-
fine the luminal B subgroup and were overrepresented in
the pathway analysis as well (see above). EGRF is not
only a receptor for EGF (Epidermal growth-factor), but
also for other members of the EGF family and it is
involved in the control of cell growth and differentiation.
For the geneset of the normal-like subgroup, we
observed overrepresentation of NRF1 family of TFBS
(Additional file 9: Table S2).
Presence of promoter modules in genes that define the
ErbB2+ subgroup
The specificity of promoter-controlled gene regulation
may depend on the relative organization of the elements
within the promoter rather than solely on individual ele-
ments [20–22]. Genes expressed in the same functional
context do often share promoter modules [20,21]. The
binding elements are often occupied differently in
different tissues, and these differences can be used to de-
rive all type-specific sub-modules in silico. A promoter
module may be defined as an organized group of regula-
tory elements where both order and distance should be
considered. Genes expressed in the same functional con-
text do often share promoter modules [20,21]. For the
six best genes of the ErbB2+ over-expressing cluster, a
common framework consisting of NF-κB and ETS1 tran-
scription factor binding sites was found (Figure 4). The
ETS are fundamentally important TFs with roles in cell
development, cell differentiation, cell proliferation, apop-
tosis and tissue remodeling (reviewed [23]). The family is
characterized by an evolutionarily conserved DNA-bind-
ing domain that regulates expression by binding to a
purine-rich core sequence in cooperation with other
TFs. Most of the proteins in the ETS family are down-
stream nuclear targets of ras-MAP kinase signaling, and
the deregulation of ETS genes results in the malignant
transformation of cells [24] It has previously been
reported that mutant TP53 required ETS1 to synergistic-
ally activate the expression of ABCB1. ETS1 was shown
to interact exclusively with mutant TP53 in vivo, but not
with wild-type TP53 [25]. High levels of ETS1 expression
were associated with poorer prognosis [26]. The pres-
ence of a promoter module constituting of NF-κB and
ETS has been reported previously in genes co-regulated
in mitogen-stimulated T-cells [27]. Interactions between
Figure 4 Common Framework in the ErbB2+ subgroup. The common framework consisting of NF-κB and Ets found in the 6 cluster defining
genes of the ErbB2+ over-expressing subgroup. Distance to next element is between 29 and 79 bp (ETSF). Directions (up/down) of the elements
indicate presence of hits on sense or antisense strands respectively.
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members of the ETS family and NF-κB have been
described previously. ETS1 induces IKKα expression.
IKKα is a kinase that marks the NF-κB inhibitor IκB for
degradation, and active NF-κB is translocated to the nu-
cleus. ETS1-mediated activation of IKKα is negatively
regulated by TP53 binding to ETS1. TP53 physically
interacts with ETS1 and specifically inhibits ETS1
induced IKKα promoter activity. Loss of TP53-mediated
control over ETS1 dependent transactivation of IKKα
may represent a novel pathway for the constitutive acti-
vation of NF-κB mediated gene expression and therapy
resistance in cancer cells [28] TP53 is therefore an ETS1
and ETS2 target gene [29]. NF-κB controls a broad
spectrum of genes by a variety of mechanisms in re-
sponse to diverse environmental changes. NF-κB may be
a universal regulator, while ETS could reflect cell-type or
stimulation specific differences since ETS binding sites
were detected in a fraction of the NF-κB controlled
genes.
Over-representation of TP53 mutations in the tumors that
belong to the ErbB2+ and basal-like subgroups
In human breast tumors, the two tumor subgroups exhi-
biting the most prominent activation of putative NF-κB
target genes (ErbB2+ and Basal-like) also harbored the
highest frequency of p53 mutations. 86% of the patients
 V$PAX4 
 V$ARID 
 V$BTBF 
 O$TF2B 
 V$GCNR 
 V$NRF1 
 V$PAX1 
 O$PTBP 
 V$GABF 
 V$CHOP 
 V$OAZF 
 V$MEF3 
 V$ZF5F 
 O$TF3C 
 V$GUCE 
 V$PAX9 
 V$WHNF 
 V$CSEN 
 V$FXRE 
 V$CDEF 
 V$PAX8 
 V$TCFF 
 V$BRAC 
 V$GCMF 
 V$PLAG 
 O$MTEN 
 V$THAP 
 V$HMTB 
 V$XBBF 
 V$RBP2 
 V$E2FF 
 V$OCTB 
 V$PLZF 
 V$GREF 
 V$PURA 
 V$SF1F 
 V$NFKB 
 V$RREB 
 V$PIT1 
 V$AP1F 
 V$DMTF 
 V$ZF35 
 V$MAZF 
 V$YBXF 
 V$SP1F 
 V$RBIT 
 O$XCPE 
 V$MOKF 
 V$BPTF 
 V$AHRR 
 V$BNCF 
 V$ZBPF 
 V$CHRF 
 V$NRSF 
 V$CABL 
 V$HICF 
 V$CDXF 
 V$MYOD 
 V$MTF1 
 V$PAX2 
 V$DICE 
 V$CTCF 
 V$GZF1 
 V$INSM
 V$SREB 
 V$NOLF 
 V$DEAF 
 V$BRNF 
 V$AP2F 
 V$CP2F 
 V$ATBF 
 V$TEAF 
 V$SRFF 
 V$EGRF 
 V$STAT 
 V$MZF1 
 V$AP4R 
 O$INRE 
 V$NBRE 
 V$GRHL 
 V$EKLF 
 V$MITF 
 V$CHRE 
 V$HNF1 
 V$LHXF 
 V$CART 
 V$NEUR 
 V$E4FF 
 V$SNAP 
 V$PPAR 
 V$HAML 
 V$RP58 
 V$NKX6 
 V$RU49 
 V$P53F 
 V$PBXC 
 V$OCT1 
 V$FAST 
 V$RBPF 
 V$PTF1 
 V$RUSH 
 V$YY1F 
 V$SATB 
 V$GKLF 
 O$TF2D 
 O$VTBP 
 V$HNF6 
 V$HIFF 
 V$SMAD 
 V$ZNFP 
 V$EREF 
 V$HOXH 
 V$CEBP 
 V$GFI1 
 V$NFAT 
 V$HESF 
 V$EBOX 
 V$GLIF 
 V$BARB 
 V$PAX5 
 V$PERO 
 V$PRDF 
 V$RORA 
 V$IRFF 
 V$ZFHX 
 V$SPZ1 
 V$CAAT 
 V$DMRT 
 V$HOXC 
 V$FKHD 
 V$GATA 
 V$MYBL 
 V$EVI1 
 V$HEAT 
 V$PAX3 
 V$LEFF 
 V$IKRS 
 V$CIZF 
 V$RXRF 
 V$AARF 
 V$MEF2 
 V$NR2F 
 V$AP1R 
 V$ZFIA 
 V$PDX1 
 V$MYT1 
 V$ETSF 
 V$PAX6 
 V$PARF 
 V$BCL6 
 V$HOMF 
 V$TALE 
 V$CREB 
 V$HAND 
 V$AIRE 
 V$CLOX 
 V$HOXF 
 V$NF1F 
 V$STAF 
 V$SORY 
 V$NKXH 
 
Ba
sa
l 
 
ER
BB
2+
 
 
Lu
m 
A 
 
Lu
m 
B 
 
No
rm
al
-l
ik
e 
 V$IKRS 
 V$CIZF 
 V$RXRF 
 V$AARF 
 V$MEF2 
 V$NR2F 
 V$AP1R 
 V$ZFIA 
 V$PDX1 
 V$MYT1 
 V$ETSF 
 V$PAX6 
 V$PARF 
 V$BCL6 
 V$HOMF 
 V$TALE 
 V$CREB 
 V$HAND 
 V$AIRE 
 V$CLOX 
 V$HOXF 
 V$NF1F 
 V$STAF 
 V$SORY 
 V$NKXH 
 V$PAX4 
 V$ARID 
 V$BTBF 
 O$TF2B 
 V$GCNR 
 V$NRF1 
 V$PAX1 
 O$PTBP 
 V$GABF 
 V$CHOP 
 V$OAZF 
 V$MEF3 
 V$ZF5F 
 O$TF3C 
 V$GUCE 
 V$PAX9 
 V$WHNF 
 V$CSEN 
 V$FXRE 
 V$CDEF 
 V$PAX8 
 V$TCFF 
 V$BRAC 
 V$GCMF 
 V$PLAG 
Top 25 TFBS families with
most different fold factor 
overrepresentation between
the subtypes
Top 25 TFBS families with
least different fold factor 
overrepresentation between
the subtypes
 
B
a
s
a
l
 
 
E
R
B
B
2
+
 
 
L
u
m
 
A
 
 
L
u
m
 
B
 
 
N
o
r
m
a
l
-
l
Figure 5 Heatmap of fold overrepresentations for the TFBS families ranked according to their distance from center. Out of all, 25 TFBS
matrix families top ranked according to their distance from the centroid of fold-overrepresentation matrix, are highlighted.
Joshi et al. BMC Genomics 2012, 13:199 Page 8 of 12
http://www.biomedcentral.com/1471-2164/13/199
in the ErbB2+ subgroup had TP53 mutations in their
tumors and all the genes that are abnormally expressed
in this tumor type have NF-κB binding sites in their pro-
moter (Figure 3C). There is an evidence that NF-κB can
regulate TP53 expression and that NF-κB is required for
TP53-dependent cell death [30]. In turn, TP53 activates
NF-κB through the RAF/MEK1/p90 pathway [30]. The
TP53 protein interacts with NF-κB and enhances its
transcriptional activity and its anti-apoptotic efficacy.
Over-expression of ErbB2 is known to induce the clas-
sical NF-κB pathway [31,32]. The estrogen receptor (ER)
can bind physically to NF-κB to inhibit its DNA binding
functions, hitherto repressing gene expression [33].
Therefore the NF-κB pathway was shown to be a major
stroma-tumor signaling mediator in ER negative tumors
with over-expression of ErbB2 [8]. NF-κB signaling has
been associated with doxorubicin resistance, and agents
blocking NF-κB function have been proven beneficial in
the treatment of tumors in combination with standard
anti-cancer therapies [34].
Over-represented transcription factor families within the
promoter sequences
We observed the over-representation of V$BTBF (kaiso),
V$OAZF and V$PAX8 in basal and ERBB2+ tumor asso-
ciated gene promoters (Figure 5, Additional file 10: Table
S3). Kaiso group of transcription factors are known to
show nuclear accumulation during active mitosis [35]
and their over-representation indicates potential func-
tional role in these two subtypes showing aggressive
tumor progression and high cell proliferation. PAX8 ac-
tivity has also been observed in metastatic renal tumors
[36]. Precise role of PAX8 and OAZF groups of tran-
scription factors is yet unknown in breast cancers.
ERBB2+ gene promoters also show over-representation
of V$NFKB, Pleomorphic adenoma gene associated
V$PLAG and ras-responsive element binding protein
associated V$RREB families of TFBS. Activity of
NFKappa B is already discussed in the earlier section.
RREB1 activity plays a role in TP53 mediated apoptosis
[37] that gets perturbed in absence of functional TP53,
which is a common phenomenon in ERBB2+ tumors.
Both luminal groups involve over-representation of PAX
subgroup 1 member TFBS’s- V$PAX1, V$PAX9 and
V$ZF5F families. PAX9 activity is known to be a marker
of better prognosis. Overrepresentation of V$P53F,
V$HOXF, V$CLOX, V$PARF and V$GATA was
observed specifically in luminal A group in which estro-
gen receptor signaling is a predominant characteristic.
The transcription factors corresponding to V$PARF
group (PAR bZIP TFs) are mediators in oxidative stress-
induced apoptosis [38]. In the luminal B group of pro-
moters, we observed over-representation of V$EGRF, V
$CTCF and V$EKLF etc. Egr-1 which corresponds to the
V$EGRF family is known to be associated with cell cycle
entry in response to growth stimuli [39]. We also
observed significant over-representation of V$NRF1 in
both normal-like and luminal B group of promoters.
NRF-1 transcription factor is an oxidant-sensitive tran-
scription factor, usually found in ER positive breast can-
cers [40] and is shown to be associated with higher
tumor grade [41].
By using the Wilcoxon rank sum test, we observed sig-
nificantly elevated mRNA expressions of ESR1 and PGR
in Luminal A or Luminal samples compared to the basal
ones (p< 1.0e-6), with non-significant differences in
ERBB2 expressions. As expected ERBB2 was significantly
upregulated in ERBB2+ tumors along with downregu-
lated ESR1 and PGR, compared to the rest (p< 1.0e-4).
Regulation by many transcription factors shown overre-
presented here in ER+ ve or ER-ve subtypes is not well
characterized in context of estrogen and progesterone re-
ceptor activity. However, overrepresentation of some of
the TFBS, such as GATA, BTBF, NF Kappa B – appear
to be consistent with prevailing knowledge about the
subtypes and their ER/PR or Her2 status.
Thus functions of the TF genes corresponding to the
over-represented TFBS families hint the predominant
characteristics of the subtypes. Findings from the above
in silico analysis will be further validated in reporter
studies and ChIP analyses. The approach of identifying
overrepresented TFBS in a set of coordinately expressed
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Figure 6 Correlation between TF overrepresentation and corresponding TF gene in each subtype. Correlation between geometric mean
of TF gene expressions in each subtype (shown as red bars) and their corresponding TF matrix family overrepresented in subtype-specific
promoter sequences (shown as blue points) is plotted.
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genes under a particular disease class or condition can
improve the specificity and noise tolerance [42]. How-
ever, its main limitation is that it does not account for
the role of local chromatin environment constituted by
structural properties, epigenetic modification etc. The
local chromatin environment can offer condition-spe-
cific functionality to the existing TFBSs in a set of
promoters.
Promoter sequences extending from 500 bp upstream to
100 bp downstream relative to TSS typically contain core
promoter elements, CpG islands, downstream promoter
element and other components of transcriptional machin-
ery. Besides, this region has been demonstrated to have high
density of positional as well as comparative TFBS [43],
many of which are typically location sensitive. Thus limiting
the analysis to this proximal promoter region, rather than
analyzing the broader region (i.e. -1000 bp to +500 bp rela-
tive to the TSS) – could reduce false positives in TFBS over-
representation. However, by that very limitation we may
omit important information about second alternative pro-
moters and distant control loci, which are therefore outside
the scope of this analysis.
Correlation between actual abundance of TFs and
frequency of their BS in the genes defining the clusters
Some of the TFBS family overrepresentations were posi-
tively correlated with the geometric means of subtype-spe-
cific mRNA expressions of their corresponding TF genes.
(Shown in Figure 6, Additional file 11: Table S4). The ra-
tionale underlying the use of geometric mean is that gene
expression intensity values follow lognormal distribution.
Biological uncertainty in a correlation between the
abundance of TFs and frequency of their BS might be
attributed to several factors. The most common and ob-
vious reason could be mutant or copy number altered
TF. Moreover, here we have not accounted for the
expressions of downstream targets of the TFs. It is note-
worthy that mutations (point mutation and copy number
alteration) in TFs can also have an impact on the level of
expression of the downstream genes. For instance, a mu-
tant TP53, which is still highly expressed, may not
recognize the original binding sites anymore, leading to a
drop in the expression of the target genes.
Conclusion
Here we report that the promoter composition of the
genes that strongly predict the patient subgroups is dis-
tinct. The gene classes showed a clear separation when
based solely on their promoter composition. This finding
suggests that studying those transcription factors asso-
ciated to the observed expression pattern in breast can-
cers may lead us to important biological pathways
responsible for the regulation of gene expression in
breast cancer.
Additional files
Additional file 1: Table S1. Subtype-specific gene list. Table shows
the 197 subtype-specific best discriminatory genes, which is a subset of
the intrinsic gene-list.
Additional file 2: Figure S1. Histogram of z-scores of
overrepresentation. Histogram of TFBS matrix family overrepresentation
observed in subtype-specific promoters compared to the reference
genomic promoter background shown as z-scores.
Additional file 3: Figure S2. Direct interactions between genes
defining subtypes. Subtype-relevant key driver interactions for Luminal
A, B and ERBB2+ subtypes.
Additional file 4: Figure S3. Protein-protein interactions and TF
interactions associated with Luminal A subtype. Network shown here
is based on the luminal A specific genelist.
Additional file 5: Figure S4. Protein-protein interactions and TF
interactions associated with Luminal B subtype. Network shown here
is based on the luminal B specific genelist.
Additional file 6: Figure S5. Protein-protein interactions and TF
interactions associated with ERBB2+ subtype. Network shown here is
based on the ERBB2+ subtype-specific genelist.
Additional file 7: Figure S6. Protein-protein interactions and TF
interactions associated with basal subtype. Network shown here is
based on the basal subtype-specific genelist.
Additional file 8: Figure S7. Protein-protein interactions and TF
interactions associated with normal-like subtype. Network shown
here is based on the normal-like subtype-specific genelist.
Additional file 9: Table S2. TFBS overrepresentation in subtypes-
specific gene promoters. List of significantly over-represented
transcription factor binding site families in subtypes of breast cancers at
the cut-off level of z- score>=2.0.
Additional file 10: Table S3. Over-representation of potential TFBS
in subtype-specific promoter sequences. Table shows the fold over-
representation of potential transcriptional factor hits (represented as TFBS
families) in subtype- specific gene promoter sequences.
Additional file 11: Table S4. Correlation between TFBS
overrepresentation and mRNA expression of corresponding TF
genes. Table displays the Pearson’s correlation between the geometric
mean of expression values of transcription factor genes in subtypes and
fold overrepresentation of corresponding TFBS families.
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